X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CRD-740 is phosphodiesterase-9 (“PDE9”) inhibitor, the enzyme that metabolizes cardiac cGMP generated by the natriuretic peptide receptor (NPR) pathway ,for the treatment of heart failure.
Lead Product(s): CRD-740
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CRD-740
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
The investment will support the advancement of Cardurion’s pipeline of cardiovascular drug candidates includes a PDE9 inhibitor and a CaMKII inhibitor program, and enable the Company to scale its team, and create an industry-leading platform.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Bain Capital Life Sciences
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
